Weighing the outcomes

Nature Biotechnology

Volumn 26, Issue 2, 2008, Pages 173-182

  Russo, Michael J ^a   Balekdjian, David ^a  

^a Bruckner Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BIOLOGICAL PRODUCT; CETUXIMAB; CVBT 141H; FIBROBLAST GROWTH FACTOR 1; IMATINIB; UNCLASSIFIED DRUG;

CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CORONARY ARTERY DISEASE; DRUG COST; DRUG INDUSTRY; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MANAGED CARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; SHORT SURVEY;

BIOLOGICAL PRODUCTS; BIOTECHNOLOGY; INDUSTRY; MARKETING; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; UNITED STATES;

EID: 38949160468     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0208-173     Document Type: Short Survey

References (1)

1. IMS Health. IMS Health Reports Global Pharmaceutical Market Grew 7.0 Percent in 2006, to $643 Billion (IMS, Norwalk, CT, USA, March 20, 2007). 〈http://www.imshealth.com/ims/portal/front/articleC/0,2777, 6599_3665_80560241,00.html〉